Serum B12 at 7 days post-injection is equivalent (Andrs et al., 2018)
SLU-PP-332 is a novel synthetic pan-agonist of the estrogen-related receptors (ERR, ERR, ERR), originally developed at Saint Louis University and characterised in recent pre-clinical literature as an exercise mimetic. It is widely studied in research models exploring mitochondrial biogenesis, fatty-acid oxidation, and metabolic endurance
Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product
Some research framings use a 5-days-on / 2-off pattern to build in a weekly break
This comprehensive dosage guide examines the research-backed protocols, administration methods, timing strategies, and safety considerations based on clinical studies involving over 900 participants